Jinsong Jia

575 total citations
39 papers, 321 citations indexed

About

Jinsong Jia is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Jinsong Jia has authored 39 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hematology, 11 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Jinsong Jia's work include Acute Myeloid Leukemia Research (23 papers), Hematopoietic Stem Cell Transplantation (13 papers) and Multiple Myeloma Research and Treatments (9 papers). Jinsong Jia is often cited by papers focused on Acute Myeloid Leukemia Research (23 papers), Hematopoietic Stem Cell Transplantation (13 papers) and Multiple Myeloma Research and Treatments (9 papers). Jinsong Jia collaborates with scholars based in China. Jinsong Jia's co-authors include Xiao‐Jun Huang, Hao Jiang, Qian Jiang, Hong‐Hu Zhu, Ya‐Zhen Qin, Lan‐Ping Xu, Jing Wang, Xiaohui Zhang, Yu Wang and Guo‐Rui Ruan and has published in prestigious journals such as Blood, Frontiers in Immunology and British Journal of Haematology.

In The Last Decade

Jinsong Jia

39 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jinsong Jia China 12 280 91 90 75 67 39 321
Ansu Abu Alex India 9 202 0.7× 150 1.6× 94 1.0× 32 0.4× 68 1.0× 22 334
Mariacarla De Simone Italy 11 252 0.9× 210 2.3× 83 0.9× 39 0.5× 74 1.1× 14 384
Gioia Colafigli Italy 11 270 1.0× 99 1.1× 30 0.3× 178 2.4× 54 0.8× 41 333
Rossana Putzulu Italy 9 133 0.5× 157 1.7× 55 0.6× 42 0.6× 51 0.8× 26 295
Alessandra Cupri Italy 11 214 0.8× 67 0.7× 37 0.4× 88 1.2× 76 1.1× 27 313
Ramdane Belhocine France 9 183 0.7× 21 0.2× 33 0.4× 37 0.5× 67 1.0× 18 223
G. Zeile Germany 5 366 1.3× 105 1.2× 107 1.2× 73 1.0× 85 1.3× 6 410
Yoshitoshi Ohtsuka Japan 9 138 0.5× 75 0.8× 33 0.4× 62 0.8× 38 0.6× 20 208
Diane S. Sempek United States 6 323 1.2× 39 0.4× 57 0.6× 66 0.9× 143 2.1× 7 397
Caterina Stefanizzi Italy 10 177 0.6× 47 0.5× 32 0.4× 114 1.5× 62 0.9× 25 237

Countries citing papers authored by Jinsong Jia

Since Specialization
Citations

This map shows the geographic impact of Jinsong Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jinsong Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jinsong Jia more than expected).

Fields of papers citing papers by Jinsong Jia

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jinsong Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jinsong Jia. The network helps show where Jinsong Jia may publish in the future.

Co-authorship network of co-authors of Jinsong Jia

This figure shows the co-authorship network connecting the top 25 collaborators of Jinsong Jia. A scholar is included among the top collaborators of Jinsong Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jinsong Jia. Jinsong Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Jing, Siqi Li, Ying‐Jun Chang, et al.. (2024). Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial. Journal for ImmunoTherapy of Cancer. 12(11). e010355–e010355. 3 indexed citations
2.
Wang, Huaquan, Guangsheng He, Jinsong Jia, et al.. (2023). Efficacy and safety of avatrombopag in aplastic anemia patients with liver disease. Journal of Translational Internal Medicine. 11(1). 90–93. 5 indexed citations
3.
Zhang, Yawen, et al.. (2023). Transfusion-dependent non-severe aplastic anemia: characteristics and outcomes in the clinic. Frontiers in Immunology. 14. 1197982–1197982. 1 indexed citations
4.
5.
Li, Ruixin, Ningling Wang, Xingxing Chai, et al.. (2023). Prolonged use of eltrombopag in patients with severe aplastic anemia in the real world. Clinical and Experimental Medicine. 23(6). 2619–2627. 3 indexed citations
6.
Jia, Jinsong, Shasha Wang, Kang Ying, Xiujuan Liu, & Lan‐Ping Xu. (2023). Porcine antilymphocyte globulin versus rabbit antithymocyte globulin for intensive immunosuppressive therapy of acquired aplastic anemia: A meta-analysis and systematic review. International Journal of Clinical Pharmacology and Therapeutics. 61(12). 551–560. 1 indexed citations
7.
8.
9.
Li, Ruixin, et al.. (2022). A real-world experience of eltrombopag plus rabbit antithymocyte immunoglobulin–based IST in Chinese patients with severe aplastic anemia. Annals of Hematology. 101(11). 2413–2419. 5 indexed citations
10.
Liu, Jing, Xiaohong Liu, Jinsong Jia, et al.. (2022). Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study. Leukemia Research Reports. 18. 100354–100354. 2 indexed citations
11.
Huang, Lifang, Li Li, Jinsong Jia, et al.. (2022). Frontline Therapy Options for Adults With Newly Diagnosed Severe Aplastic Anemia: Intensive immunosuppressive Therapy Plus Eltrombopag or Matched Sibling Donor Hematopoietic Stem Cell Transplantation?. Transplantation and Cellular Therapy. 28(9). 586.e1–586.e7. 7 indexed citations
12.
Jiang, Hao, Xiaohong Liu, Jun Kong, et al.. (2021). Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia & lymphoma. 62(12). 2949–2956. 14 indexed citations
13.
14.
Zhu, Hong‐Hu, Jinsong Jia, Qian Jiang, et al.. (2017). Determinants of Early Death and Outcomes for Acute Promyelocytic Leukemia in the Arsenic Era: A Real World Study. Blood. 130. 1340–1340. 1 indexed citations
15.
Wang, Jing, Qian Jiang, Lan‐Ping Xu, et al.. (2017). Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation. 24(4). 741–750. 34 indexed citations
16.
Zhu, Hong‐Hu, et al.. (2017). The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. Leukemia Research. 65. 14–19. 17 indexed citations
17.
18.
Jiang, Bin, Kai‐Yan Liu, Lan‐Ping Xu, et al.. (2015). [Outcome of patients with adult acute lymphoblastic leukemia between 2000 and 2013: experience from single center].. PubMed. 36(9). 726–32. 4 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ansu Abu Alex Breakdown of academic impact, for papers by Mariacarla De Simone Breakdown of academic impact, for papers by Gioia Colafigli Breakdown of academic impact, for papers by Rossana Putzulu Breakdown of academic impact, for papers by Alessandra Cupri Breakdown of academic impact, for papers by Ramdane Belhocine Breakdown of academic impact, for papers by G. Zeile Breakdown of academic impact, for papers by Yoshitoshi Ohtsuka Breakdown of academic impact, for papers by Diane S. Sempek Breakdown of academic impact, for papers by Caterina Stefanizzi
Rankless by CCL
2026